- Home
- COHR vs MRNA Comparison
COHR vs MRNA Comparison
Compare COHR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COHR | MRNA |
|---|---|---|
| Founded | 1971 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.2B | 61.6B |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | COHR | MRNA |
|---|---|---|
| Price | $315.82 | $154.25 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 12 |
| Target Price | ★ $264.62 | $34.27 |
| AVG Volume (30 Days) | 5.1M | ★ 23.7M |
| Earning Date | 05-06-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 892.31 | 21.77 |
| EPS | ★ 4.12 | N/A |
| Revenue | $1,158,794,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $21.72 | $9.36 |
| Revenue Next Year | $24.63 | $15.43 |
| P/E Ratio | $71.85 | ★ N/A |
| Revenue Growth | ★ 19.21 | 4.29 |
| 52 Week Low | $102.14 | $22.28 |
| 52 Week High | $440.00 | $176.66 |
Technical Indicators
Market Signals| Indicator | COHR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 54.19 | 64.57 |
| Support Level | $297.53 | $46.85 |
| Resistance Level | $327.78 | $156.42 |
| Average True Range (ATR) | 15.95 | 9.54 |
| MACD | 2.90 | -1.67 |
| Stochastic Oscillator | 88.50 | 78.72 |
Price Performance
Historical ComparisonAbout COHR Coherent Corp.
Coherent Corp is a vertically integrated manufacturing company that develops, manufactures, and markets lasers, transceivers, and other optical and optoelectronic devices, modules, and systems, as well as engineered materials, for use in the communications, industrial, instrumentation, and electronics markets. Its reporting segments are Datacenter Communications and Industrial. Its geographic areas are North America, Europe, China, Japan, and the rest of the world.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.